Related Experiment Video

Updated: Jun 28, 2025

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

4.8K

The Possible Effect of β-Blocker Use on the Circulating MMP-2/TIMP-2 System in Patients with Chronic Kidney Disease

Magdalena Kopańko1, Magdalena Zabłudowska1, Dariusz Pawlak2

  • 1Department of Monitored Pharmacotherapy, Medical University of Bialystok, Mickiewicza 2C, 15-222 Bialystok, Poland.

Journal of Clinical Medicine
|April 13, 2024
PubMed

Insights

Beta-blocker use in chronic kidney disease (CKD) patients was associated with reduced levels of interleukin-6 (IL-6) and the metalloproteinase 2 (MMP-2)/tissue inhibitor of metalloproteinase 2 (TIMP-2) system. This suggests a potential role for beta-blockers in managing inflammation and vascular remodeling in CKD.

Area of Science:

  • Cardiology
  • Nephrology
  • Biochemistry

Background:

  • Chronic kidney disease (CKD) is associated with increased inflammation and abnormal vascular remodeling.
  • The metalloproteinase 2 (MMP-2) and tissue inhibitor of metalloproteinase 2 (TIMP-2) system plays a role in vascular remodeling.
  • Proinflammatory cytokines like interleukin-6 (IL-6) are elevated in CKD.

Purpose of the Study:

  • To investigate the effect of beta-adrenoceptor antagonists (beta-blockers) on the MMP-2/TIMP-2 system in CKD patients.
  • To assess the impact of beta-blockers on proinflammatory cytokines and oxidative stress markers in CKD.

Main Methods:

  • Cross-sectional study comparing CKD patients on beta-blockers versus those not on beta-blockers.
  • Measurement of circulating MMP-2, TIMP-2, TNF-α, IL-6, and Cu/Zn SOD levels.
  • Statistical analysis to determine associations between beta-blocker use and measured biomarkers.

Main Results:

  • CKD patients on beta-blockers exhibited significantly lower levels of MMP-2, TIMP-2, and IL-6 compared to those not on beta-blockers.
  • No significant difference in Cu/Zn SOD levels was observed between the groups.
  • MMP-2 and TIMP-2 showed a strong independent association in both groups.

Conclusions:

  • Beta-blocker use in CKD is associated with reduced IL-6 and the MMP-2/TIMP-2 system.
  • This finding provides a potential pharmacological basis for using beta-blockers to mitigate inflammation and vascular remodeling in CKD.
  • Further research is warranted to explore the therapeutic implications of these findings.
Keywords:
chronic kidney disease (CKD)inflammationmetalloproteinase 2 (MMP-2)oxidative stresstissue inhibitor of metalloproteinase 2 (TIMP-2)β-blockers

More Related Videos

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection10:25

Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection

Published on: November 10, 2021

1.8K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

559

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
613
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
627
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
441
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
88